JP6970115B2 - デングウイルス複製阻害剤としての置換インドリン誘導体 - Google Patents

デングウイルス複製阻害剤としての置換インドリン誘導体 Download PDF

Info

Publication number
JP6970115B2
JP6970115B2 JP2018550545A JP2018550545A JP6970115B2 JP 6970115 B2 JP6970115 B2 JP 6970115B2 JP 2018550545 A JP2018550545 A JP 2018550545A JP 2018550545 A JP2018550545 A JP 2018550545A JP 6970115 B2 JP6970115 B2 JP 6970115B2
Authority
JP
Japan
Prior art keywords
compound
mmol
reduced pressure
under reduced
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018550545A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019510034A (ja
JP2019510034A5 (enExample
Inventor
ルドルフ ロマニー ケステルイン，バート
ジャン−マリー ベルナール ラボワッソン，ピエール
ボンファンティ，ジャン−フランソワ
アリス マリー−イヴ バルディオ，ドロセー
ディディエ エム． マーチャン，アルノー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KU Leuven
Original Assignee
KU Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KU Leuven filed Critical KU Leuven
Publication of JP2019510034A publication Critical patent/JP2019510034A/ja
Publication of JP2019510034A5 publication Critical patent/JP2019510034A5/ja
Application granted granted Critical
Publication of JP6970115B2 publication Critical patent/JP6970115B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2018550545A 2016-04-01 2017-03-31 デングウイルス複製阻害剤としての置換インドリン誘導体 Expired - Fee Related JP6970115B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16163488.6 2016-04-01
EP16163488 2016-04-01
PCT/EP2017/057661 WO2017167951A1 (en) 2016-04-01 2017-03-31 Substituted indoline derivatives as dengue viral replication inhibitors

Publications (3)

Publication Number Publication Date
JP2019510034A JP2019510034A (ja) 2019-04-11
JP2019510034A5 JP2019510034A5 (enExample) 2020-04-23
JP6970115B2 true JP6970115B2 (ja) 2021-11-24

Family

ID=55650311

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018550545A Expired - Fee Related JP6970115B2 (ja) 2016-04-01 2017-03-31 デングウイルス複製阻害剤としての置換インドリン誘導体

Country Status (31)

Country Link
US (2) US10689340B2 (enExample)
EP (1) EP3436437B1 (enExample)
JP (1) JP6970115B2 (enExample)
KR (1) KR102359776B1 (enExample)
CN (1) CN108884037B (enExample)
AR (1) AR108046A1 (enExample)
AU (1) AU2017242894B2 (enExample)
CA (1) CA3013406C (enExample)
CL (1) CL2018002758A1 (enExample)
CO (1) CO2018009563A2 (enExample)
CR (1) CR20180493A (enExample)
DK (1) DK3436437T3 (enExample)
EA (1) EA037988B1 (enExample)
EC (1) ECSP18073293A (enExample)
ES (1) ES2884067T3 (enExample)
HR (1) HRP20211278T1 (enExample)
HU (1) HUE055577T2 (enExample)
IL (1) IL261948B (enExample)
JO (1) JOP20170069B1 (enExample)
LT (1) LT3436437T (enExample)
MX (1) MX381634B (enExample)
MY (1) MY195194A (enExample)
PE (1) PE20181778A1 (enExample)
PH (1) PH12018502077A1 (enExample)
SG (1) SG11201808409XA (enExample)
SI (1) SI3436437T1 (enExample)
TW (1) TWI723148B (enExample)
UA (1) UA125296C2 (enExample)
UY (1) UY37182A (enExample)
WO (1) WO2017167951A1 (enExample)
ZA (1) ZA201806482B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020520950A (ja) * 2017-05-22 2020-07-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
HRP20210847T1 (hr) 2016-03-31 2021-07-23 Janssen Pharmaceuticals, Inc. Supstituirani derivati indola kao inhibitori replikacije denga virusa
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201892200A1 (ru) 2016-04-01 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) * 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3060583C (en) 2017-05-22 2024-06-04 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
PH12022551160A1 (en) 2019-11-15 2023-09-25 Janssen Pharmaceuticals Inc Treatment and prevention of dengue disease
WO2025248536A1 (en) * 2024-05-29 2025-12-04 Zydus Lifesciences Limited Novel oxime derivatives to treat viral infections
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease
CN121378100B (zh) * 2025-12-24 2026-04-21 浙江大学医学院附属第二医院 一种苯并[g]吲哚衍生物及其在制备抗登革热药物中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1200899A (en) 1997-10-27 1999-05-17 Eli Lilly And Company Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
EP1519735A4 (en) 2001-12-12 2006-01-11 Conforma Therapeutic Corp ASSAYS AND DEVICES FOR DETERMINING AND MODULATING HSP90 BINDING ACTIVITY
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
CN101103026A (zh) 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
AU2006221080A1 (en) 2005-02-09 2006-09-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
CN102056483A (zh) 2008-06-03 2011-05-11 西佳技术公司 用于治疗或预防登革病毒感染的小分子抑制剂
EP2331499B1 (en) 2008-08-19 2016-09-21 Janssen Pharmaceutica NV Cold menthol receptor antagonists
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
EA201290575A1 (ru) 2010-01-15 2013-01-30 Джилид Сайэнс, Инк. Ингибиторы вирусов flaviviridae
WO2011120025A1 (en) 2010-03-26 2011-09-29 Glaxo Group Limited Indazolyl-pyrimidines as kinase inhibitors
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
JP6505727B2 (ja) 2014-01-31 2019-04-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヘテロ環式ｐ２’基を有する第ｘｉａ因子阻害剤としてのマクロ環
NO2721243T3 (enExample) 2014-10-01 2018-10-20
US9944598B2 (en) 2014-10-01 2018-04-17 Janssen Pharmaceuticals, Inc. Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
BR112017006708A2 (pt) * 2014-10-01 2017-12-26 Janssen Pharmaceuticals Inc indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue
PH12017501272B1 (en) * 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3002214C (en) 2015-11-03 2022-01-04 Zoetis Services Llc Sol-gel polymer composites and uses thereof
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
HRP20210847T1 (hr) 2016-03-31 2021-07-23 Janssen Pharmaceuticals, Inc. Supstituirani derivati indola kao inhibitori replikacije denga virusa
UY37174A (es) 2016-03-31 2017-10-31 Takeda Pharmaceuticals Co Un compuesto heterocíclico que tiene una acción inhibidora de monoacilglicerol lipasa
US10576085B2 (en) 2016-04-01 2020-03-03 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
AU2017240801A1 (en) 2016-04-01 2018-10-25 Amgen Inc. Chimeric receptors to FLT3 and methods of use thereof
SG10201912519VA (en) 2016-04-01 2020-02-27 Kite Pharma Inc Chimeric receptors and methods of use thereof
KR102427334B1 (ko) 2016-04-01 2022-08-03 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
EA201892200A1 (ru) 2016-04-01 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX2018012016A (es) 2016-04-01 2019-01-24 Basf Se Compuestos biciclicos.
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CR20190531A (es) 2017-05-22 2020-03-05 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CA3060583C (en) 2017-05-22 2024-06-04 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020520950A (ja) * 2017-05-22 2020-07-16 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体
JP7179773B2 (ja) 2017-05-22 2022-11-29 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体

Also Published As

Publication number Publication date
ECSP18073293A (es) 2018-10-31
KR102359776B1 (ko) 2022-02-07
TWI723148B (zh) 2021-04-01
UY37182A (es) 2017-09-29
ES2884067T3 (es) 2021-12-10
SI3436437T1 (sl) 2021-11-30
CR20180493A (es) 2018-12-06
CL2018002758A1 (es) 2018-11-23
IL261948A (en) 2018-10-31
JP2019510034A (ja) 2019-04-11
EA037988B1 (ru) 2021-06-21
TW201808898A (zh) 2018-03-16
UA125296C2 (uk) 2022-02-16
CN108884037A (zh) 2018-11-23
KR20180132661A (ko) 2018-12-12
EP3436437B1 (en) 2021-05-19
BR112018068640A2 (pt) 2019-07-30
CA3013406C (en) 2024-01-09
ZA201806482B (en) 2021-04-28
PH12018502077A1 (en) 2019-07-15
HUE055577T2 (hu) 2021-12-28
CO2018009563A2 (es) 2018-09-20
US10689340B2 (en) 2020-06-23
US20200299235A1 (en) 2020-09-24
PE20181778A1 (es) 2018-11-05
LT3436437T (lt) 2021-08-25
CN108884037B (zh) 2021-05-04
IL261948B (en) 2021-07-29
AU2017242894B2 (en) 2021-07-29
MX381634B (es) 2025-03-12
HRP20211278T1 (hr) 2022-01-21
US11180450B2 (en) 2021-11-23
DK3436437T3 (da) 2021-08-09
SG11201808409XA (en) 2018-10-30
AR108046A1 (es) 2018-07-11
MX2018011785A (es) 2019-02-13
MY195194A (en) 2023-01-11
JOP20170069B1 (ar) 2021-08-17
US20190112266A1 (en) 2019-04-18
EP3436437A1 (en) 2019-02-06
AU2017242894A1 (en) 2018-08-09
EA201892219A1 (ru) 2019-03-29
CA3013406A1 (en) 2017-10-05
WO2017167951A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
JP6931357B2 (ja) デングウイルス複製阻害剤としての置換インドリン誘導体
JP7038733B2 (ja) デングウイルス複製阻害剤としての置換インドリン誘導体
KR102359776B1 (ko) 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
JP7203752B2 (ja) デングウイルス複製阻害剤としての置換インドリン誘導体
JP6888021B2 (ja) デングウイルス複製阻害剤としての置換インドール誘導体
JP7007290B2 (ja) デングウイルス複製阻害剤としての置換インドール化合物誘導体
JP2021193092A (ja) デングウイルス複製阻害剤としての一または二置換インドール誘導体
JP2021181485A (ja) デングウイルス複製阻害剤としての一または二置換インドール誘導体
KR20180002644A (ko) 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌 유도체
KR20170063802A (ko) 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌 유도체
HK1260482A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
HK1260482B (en) Substituted indoline derivatives as dengue viral replication inhibitors
HK1260967B (en) Substituted indoline derivatives as dengue viral replication inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200316

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210726

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211005

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211028

R150 Certificate of patent or registration of utility model

Ref document number: 6970115

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees